- Home
- SABS vs PLX Comparison
SABS vs PLX Comparison
Compare SABS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABS | PLX |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.6M | 168.1M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | SABS | PLX |
|---|---|---|
| Price | $4.45 | $2.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $9.80 | ★ $12.00 |
| AVG Volume (30 Days) | 414.6K | ★ 825.9K |
| Earning Date | 11-13-2025 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $114,698.00 | ★ $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | N/A | $16.65 |
| P/E Ratio | ★ N/A | $30.69 |
| Revenue Growth | N/A | ★ 35.41 |
| 52 Week Low | $1.00 | $1.32 |
| 52 Week High | $6.60 | $3.10 |
Technical Indicators
Market Signals| Indicator | SABS | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 72.95 | 57.00 |
| Support Level | $3.93 | $2.03 |
| Resistance Level | $4.21 | $2.11 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 83.87 | 76.06 |
Price Performance
Historical ComparisonAbout SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.